Phage Display Driven Identification and Computational Mapping of Macrocyclic Peptides Targeting RhoA G17V
Scientists identified a potential drug candidate against a previously untargetable cancer driver, opening possibilities for treating angioimmunoblastic lymphoma.
Phage display screening identified Z1, a macrocyclic peptide with 136 nM affinity for the neomorphic RhoA G17V oncogene driving angioimmunoblastic T-cell lymphoma—a target previously considered undruggable due to its rigid GTPase fold. This work establishes macrocyclic phage display as a generalizable platform for historically undruggable GTPases, though all current evidence is in vitro.
What the study was
- Study design
- Preclinical drug discovery (phage display + computational)
- Category
- Drug Development
- Maturity
- Exploratory
- Journal
- Biochemistry
Why it surfaced
Purely preclinical in vitro; no cellular or in vivo data; early drug discovery stage.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.